SCHEDULE: Janus Henderson Boosts Vaxcyte Stake to 10.1%

Janus Henderson Group plc has reported an increased beneficial ownership in Vaxcyte, Inc. common stock, now holding 10.1% of the class as of September 30, 2025.

Summary

• Janus Henderson Group plc reported beneficial ownership of 13,104,203 shares of VAXCYTE, INC. Common Stock.
• This represents 10.1% of the total class of securities.
• The event requiring this Schedule 13G filing occurred on September 30, 2025.
• Janus Henderson Group plc, through its indirect subsidiaries JHIUS, JHIUKL, and JHIAIFML, functions as an investment adviser to Managed Portfolios.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of VAXCYTE, INC.

Sentiment

Score: 6

Explanation: The filing itself is a routine disclosure of beneficial ownership by a large institutional investor. The increase in stake to over 10% by Janus Henderson Group plc could be viewed positively by the market as a sign of confidence, but the filing itself is purely factual and regulatory, not promotional.

Future Outlook

NA

Management Comments

• I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

This filing indicates continued institutional investor interest in VAXCYTE, INC., a biotechnology company. Large institutional holdings can provide stability and signal confidence in the company's long-term prospects within the competitive biotech sector.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be seen as a positive signal, potentially leading to increased investor confidence and stability in the stock.

Key Dates

Recommendation

The filing indicates a significant institutional investor, Janus Henderson Group plc, has increased its beneficial ownership in VAXCYTE, INC. to 10.1%. This signals confidence from a major player, which is generally a positive indicator for the company's stock stability and long-term prospects. However, a Schedule 13G is a disclosure of ownership, not an operational or financial report. Therefore, while the increased stake is noteworthy, it does not provide sufficient new fundamental information about Vaxcyte's business performance, pipeline, or market position to change a 'hold' recommendation without further analysis of the company's core business.

Keywords

VAXCYTE INC, Janus Henderson Group plc, Common Stock, Schedule 13G, Beneficial Ownership, Institutional Investor, Investment Adviser, Biotechnology, Pharmaceuticals